Black patients are underrepresented in clinical trials despite widespread efforts to increase minority participation.
Characteristics gathered from each trial included sponsor type, phase, accrual goal, start year, and toxicity. We determined the sponsor type by categorizing each trial as sponsored by industry, cooperative group, or academic investigator. Phase was categorized as phase 1 (0, I, or I/II), 2 (II or II/III), 3 (III or IV), or unknown. Trials were defined as having high toxicity if 1 of the possible treatment arms included chemotherapy, immunotherapy, surgery, brachytherapy, and/or cryoablation. All other treatments, including hormone therapy; nonimmunotherapeutic targeted agents, including biologics; external beam radiotherapy; vitamins/supplements; and nonchemotherapeutic medications, were considered low toxicity.
We investigated the use of serum creatinine (sCr) alone instead of race-adjusted measurements for renal function and the use of an absolute neutrophil count (ANC) threshold that could exclude men with benign ethnic neutropenia. Black patients have higher sCr for any given renal function, and using this measurement may falsely underestimate their renal function. 4 Similarly, the 6.7% to 8.0% of black patients with benign ethnic neutropenia, a condition defined as neutropenia (ANC<1.5 × 10 9 cells/L) without attributable cause, may be excluded despite healthy immune systems. higher to determine eligibility was more common in trials that were sponsored by academic investigators or cooperative groups vs industry (P < .001), were phase 1 or 2 vs 3 (P < .02), had lower accrual (P < .001), or had at least 1 treatment arm that was considered high toxicity (P < .001) (Table) .
Discussion | Of clinical trials in prostate cancer collected for this study, 47.9% used criteria that disproportionately excluded black patients. The reevaluation of these 2 eligibility criteria could improve minority trial enrollment. First, 41.4% of prostate cancer clinical trials excluded patients with benign ethnic neutropenia, even though evidence suggests that these patients do not have an increased risk of infection. 6 Lowering the ANC cutoff level for patients with benign ethnic neutropenia would increase the number of eligible black participants, as 89% of these patients have an ANC of 1.0 × 10 9 cells/L or higher. 5, 6 Second, 25.2% of trials used sCr alone to determine eligibility, even though black patients have higher sCr levels for any given renal function. Use of race-adjusted equations would take into account these clinically insignificant racial differences. 4 This study examined only prostate cancer clinical trials and 2 laboratory measures, which may limit the generalizability of the results. While adopting race-based differences in trial criteria may add slight logistical challenges when ensuring that patients meet trial eligibility, these adjustments would prevent healthy individuals from being excluded solely because of benign laboratory differences caused by their race.
Association of Treatment for Hodgkin Lymphoma With Estrogen Receptor Status of Subsequent Breast Cancers
Survivors of Hodgkin lymphoma (HL) have a high risk of developing a subsequent breast cancer, particularly after chest irradiation. 1, 2 Although breast cancer is a heterogeneous disease, the association between HL treatment and the estrogen receptor (ER) status of subsequent breast cancers has not been examined in large cohorts. We explored the association between radiotherapy for HL and risk of ER-positive and ER-negative breast cancer in a large, population-based cohort, accounting for chemotherapy.
Methods | We included 7355 women diagnosed with first primary HL during 1973 to 2009 at ages 10 to 39 years that were Letters
